Abstract Number: 0700 • ACR Convergence 2023
A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta
Background/Purpose: Systemic vasculitis encompasses a group of autoimmune diseases involving inflammation of blood vessels. Although a rare disease, vasculitis can present with life-threatening symptoms which…Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…Abstract Number: 1543 • ACR Convergence 2023
The Association of Frailty with Outcomes in Patients with Vasculitis
Background/Purpose: Frailty is associated with poor health outcomes including increased risk of hospitalizations, infections, and fractures. In the baseline survey of the VascStrong study, we…Abstract Number: 1646 • ACR Convergence 2023
The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis
Background/Purpose: GCA is a systemic medium-large vessel vasculitis (M-LVV) involving the cranial arteries, aorta and its major branches. Recent studies have shown that PET/CT including…Abstract Number: 2394 • ACR Convergence 2023
18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Background/Purpose: Imaging studies in patients with giant cell arteritis (GCA) and suspected large vessel vasculitis (LVV) are sensitive, increasingly available, and less aggressive than temporal…Abstract Number: 2418 • ACR Convergence 2023
Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…Abstract Number: 0236 • ACR Convergence 2023
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
Background/Purpose: Gout is associated with high comorbidity, including cardiovascular (CV), metabolic, and renal disease,1 with even higher burden in uncontrolled gout patients (pts).2 CV (myocardial…Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…Abstract Number: 0853 • ACR Convergence 2023
Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-to-medium vessel vasculitis associated with substantial morbidity and mortality, in part due to glucocorticoid exposure. Avacopan, an oral C5a…Abstract Number: 1546 • ACR Convergence 2023
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…Abstract Number: 1650 • ACR Convergence 2023
Optic Nerve Sheath Measurement as a Disease Activity Biomarker in Giant Cell Arteritis
Background/Purpose: Recently, optic nerve sheath (ONS) enhancement using contrast-enhanced magnetic resonance imaging of the brain and orbits was observed in most patients with biopsy-proven GCA.…Abstract Number: 2396 • ACR Convergence 2023
Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…Abstract Number: 2419 • ACR Convergence 2023
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Background/Purpose: Visual loss is one of the most feared complications in giant cell arteritis (GCA). Some factors have been previously associated with visual loss, as…Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 35
- Next Page »